Health
BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revello™ Vascular Covered Stent in patients with peripheral arterial disease (PAD).
About this update from Becton, Dickinson And Company
[{"type":"text","content":"FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revello™ Vascular Covered Stent in patients with peripheral arterial disease (PAD).","length":406,"tagName":"p"},{"type":"image","alt":"BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease","displaySize":"","headline":null,"caption":"BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":220,"url":"https://media.zenfs.com/en/prnewswire.com/2328d187333870b49760e04a27cf81a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3_GSjge_MWL0cLgZVqEjDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2328d187333870b49760e04a27cf81a6","width":400,"height":220}},"href":"https://mma.prnewswire.com/media/2812322/BD_Achieves_Milestone_in_AGILITY_Study.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The announcement was made in conjunction with a late-breaking clinical trial presentation at the VIVA (Vascular InterVentional Advances) 2025 conference by Dr. Sean Lyden, chairman of the Department of Vascular Surgery at Cleveland Clinic in Cleveland, Ohio, and global lead principal investigator for AGILITY.","length":310,"tagName":"p"},{"type":"text","content":"The AGILITY study represents the latest advancement by BD in self-expanding covered stent technology, aiming to address the clinical need for improved flexibility, deliverability and low-profile performance in the treatment of challenging PAD lesions.","length":251,"tagName":"p"},{"type":"text","content":""Achieving full enrollment of the iliac cohort marks a critical milestone for the AGILITY study and for patients living with peripheral arterial disease," said Dr. Lyden. "As our understanding of PAD deepens, the demand for innovative technologies that can expand our treatment options becomes increasingly critical."","length":337,"tagName":"p"},{"type":"text","content...